Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Dypha

Financiado

Cerrado

Dypha: adding the dimension of time to cell culture

The current preclinical drug development pipeline is highly inefficient with 9 out of 10 drugs failing when first tested in humans. Of those failures, between 69% and 81% is due to a lack of efficacy (52-57%) or safety (17-24%), i... ver más

31/03/2027

DEMCON SYNC BIOSYS...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

DEMCON SYNC BIOSYSTEMS BV No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-12

HORIZON-EIC-2023-TRANSITIONCHALLENGES-01: EIC Transition Challenge: Full scal... Scope:The scope of the Challenge is the maturation of Micro-Nano-Bio technologies developed in previ...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

DEMCON SYNC BIOSYSTEMS BV

1.13M€ | Lider

ESQLABS GMBH

275.25K€ | Participante

CHARLES RIVER NEDERLAND BV

395.00K€ | Participante

PrinsesMaximaCentrumvoorKind...

369.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 36 meses Fecha Inicio: 2024-03-12
Fecha Fin: 2027-03-31

Líder del proyecto

DEMCON SYNC BIOSYSTEMS BV No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The current preclinical drug development pipeline is highly inefficient with 9 out of 10 drugs failing when first tested in humans. Of those failures, between 69% and 81% is due to a lack of efficacy (52-57%) or safety (17-24%), indicating that the predictivity of currently used cell culture and animal models is not high enough. While promising human cell culture models have arisen in the last decades (e.g. pluripotent stem cell models, spheroids, organoids), the environment of these models is too simplistic to reach their full potential and to translate certain responses to humans. One of the important aspects missing in current cell culture is kinetics: many processes in the human body have response times with resolutions of seconds, minutes or hours. In standard cell culture however, such temporal resolution is absent because cell culture medium remains unchanged for typically 1-3 days. So for kinetics, scientists turn to animal models with relatively low translational success and high costs. As an alternative, complex microfluidic setups have been used to enable perfusion in vitro and demonstrated a significant amount of evidence that kinetics can improve the relevance of cell culture models. Despite the evidence, typical cell culture biologists are not taking kinetics into account because the tools to control kinetics in cell culture are too complex. We solve this problem by starting from what cell culture biologists currently use: a standard well plate. We developed a µFluidic Adaptor that can be clamped on any 96 well plate and completely replaces the fluid in the well homogenously without disturbing the cell culture. Our goal is to develop a plug-and-play peripheral system that integrates automated fluidics and microscopic readout in a fully controlled environment: the δypha System. The system uses µFluidic Adaptors that can be designed for different applications or well plate formats.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores